Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Boston Scientific (BSX)

AI-generated analysis

πŸ“ˆ Analyst Gil Blum from Needham maintained a Buy rating on Celcuity (CELC) with a price target of $157.00.

πŸ’° Celcuity shares closed last Friday at $125.65, representing significant potential upside based on the new price target.

⭐ The analyst is rated 5-stars by TipRanks with an average return of 11.7% and a 41.0% success rate.

πŸ† Street consensus for Celcuity suggests a Strong Buy rating with an average price target of $136.00.

βœ… A previous report from April 19 reiterated a Buy rating on Celcuity with a $137.00 price target.

πŸ’‰ Boston Scientific (BSX) received a Buy rating from analyst Matt Miksic at Barclays with a price target of $96.00.

πŸ“Š Miksic is rated as a 3-star analyst by TipRanks with an average return of 1.8% and a 49.2% success rate.

πŸ₯ Analyst consensus for Boston Scientific currently leans toward a Strong Buy rating with an average target of $90.00.

πŸ“‰ This consensus implies a potential 55.4% upside from current stock levels based on the average analyst price target.

πŸ”Ό A recent upgrade to Buy with a $72.00 target was issued by PerPlexity for Boston Scientific on April 23.

🧬 Celcuity reported positive Phase 3 results for its VIKTORIA-1 trial which achieved its primary endpoint.

πŸ†™ The positive trial results and competitive profile are driving the upward revision of the price target to $165.

πŸ”¬ Blum focuses his healthcare coverage on stocks including Artiva Biotherapeutics, Recursion Pharmaceuticals, and Mereo Biopharma.

🩺 Miksic covers Anteris Technologies, GE Healthcare, and Bausch + Lomb alongside Boston Scientific.

Bullish Signals
  • Analysts Gil Blum from Needham and Matt Miksic from Barclays both maintained strong Buy ratings on Boston Scientific, signaling robust institutional confidence in the company's performance.
  • Matt Miksic's price target of $96.00 for Boston Scientific implies a significant 55.4% upside potential from its current trading levels, suggesting substantial growth opportunity.
  • The general street consensus suggests a Strong Buy rating for Boston Scientific with an average price target of $90.00, reinforcing the bullish sentiment among major market participants.
  • Analyst Gil Blum has a proven track record as a 5-star analyst with an impressive 41.0% success rate and an average return of 11.7%, lending credibility to the positive outlook for Celcuity.
  • Celcuity received a $136.00 average price target from analysts, representing a 12.4% upside from current levels, which indicates a favorable valuation perspective.
Risk Factors
  • Boston Scientific's average price target of $90.00 lags significantly behind recent upgrades from other firms, such as a $72.00 target from TipRanks – PerPlexity, potentially indicating divergent analyst opinions or skepticism about the full upside.
  • Analyst Matt Miksic of Barclays has a relatively low historical track record with an average return of only 1.8% and a 49.2% success rate, which may introduce uncertainty regarding the reliability of his bullish rating and $96.00 price target for Boston Scientific.
Full Analysis
The article is not worth deleting because BSX (Boston Scientific) and CELC (Celcuity) are the central focus of the report, with specific financial data and analyst opinions provided for both. The text explicitly details new Buy ratings and price targets assigned by analysts from major firms like Needham and Barclays. For Boston Scientific, Matt Miksic of Barclays issued a Buy rating on May 5 with a price target of $96.00, which is significantly higher than the share's closing price of $56.50 at the time. This suggests an implied upside for the stock based on the analyst's projection. Regarding Celcuity, Gil Blum from Needham maintained a Buy rating with a price target of $157.00 against a closing price of $125.65. The article notes that Celcuity recently reported positive Phase 3 trial results for its drug gedatolisib in the VIKTORIA-1 study, which appears to be the primary catalyst driving the analyst's bullish sentiment. The text also references broader market consensus from sources like TipRanks, indicating a Strong Buy rating for Boston Scientific with an average price target of $90.00 and for Celcuity with a target of $136.00. Although the content includes some promotional material from TipRanks and generic commentary on the healthcare sector or market trends, these elements serve to frame the specific news about the two tickers rather than dominate the narrative. The core value of the article lies in the concrete analyst ratings, price targets, and the mention of clinical trial success for Celcuity, making it a relevant piece for investors tracking BSX or CELC.